Utd Therapeutic has a market cap of $2.32 billion; its shares were traded at around $43.81 with a P/E ratio of 9.8 and P/S ratio of 3.1.
This is the annual revenues and earnings per share of UTHR over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of UTHR.
CEO Recent Trades:
- CEO Martine A Rothblatt bought 11,823 shares of UTHR stock on 12/20/2011 at the average price of 43.92. Martine A Rothblatt owns at least 656,095 shares after this. The price of the stock has decreased by 0.25% since.
This is the insider trade history vs. stock price of UTHR. For the complete insider trading history of UTHR, click here.
Directors and Officers Recent Trades:
- Director Christopher Patusky sold 2,500 shares of UTHR stock on 04/04/2012 at the average price of 45.55. Christopher Patusky owns at least 1,300 shares after this. The price of the stock has decreased by 3.82% since.
- Director Christopher Patusky sold 2,500 shares of UTHR stock on 03/07/2012 at the average price of 45.13. Christopher Patusky owns at least 1,300 shares after this. The price of the stock has decreased by 2.92% since.
- President & COO Roger Jeffs sold 5,000 shares of UTHR stock on 02/03/2012 at the average price of 50.21. Roger Jeffs owns at least 22,062 shares after this. The price of the stock has decreased by 12.75% since.
- EVP & General Counsel Paul A Mahon sold 72,000 shares of UTHR stock on 02/02/2012 at the average price of 50. Paul A Mahon owns at least 33,600 shares after this. The price of the stock has decreased by 12.38% since.
- Director Christopher Patusky sold 2,500 shares of UTHR stock on 02/01/2012 at the average price of 49.24. Christopher Patusky owns at least 1,300 shares after this. The price of the stock has decreased by 11.03% since.
For the complete insider trading history of UTHR, click here.






RSS